Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 256Carcinoma, Non-Small-Cell Lung 212Ovarian Neoplasms 134Lung Neoplasms 107Esophageal Neoplasms 69Triple Negative Breast Neoplasms 64Stomach Neoplasms 58Fallopian Tube Neoplasms 56Squamous Cell Carcinoma of Head and Neck 52Neoplasm Metastasis 50Head and Neck Neoplasms 44Esophageal Squamous Cell Carcinoma 43Carcinoma, Ovarian Epithelial 42Neoplasms 36Endometrial Neoplasms 34Uterine Cervical Neoplasms 32Recurrence 29Adenocarcinoma Of Esophagus 24Adenocarcinoma of Lung 22Urinary Bladder Neoplasms 21Melanoma 20Carcinoma, Squamous Cell 19Carcinoma 18Small Cell Lung Carcinoma 17Prostatic Neoplasms 15Breast Neoplasms, Male 15Adenocarcinoma, Bronchiolo-Alveolar 13Peritoneal Neoplasms 12Inflammatory Breast Neoplasms 12Testicular Neoplasms 10

Interventions

Doxorubicin 8Cyclophosphamide 4Docetaxel 3Atorvastatin 3dapagliflozin 2Trastuzumab 2Chemotherapy, Adjuvant 2Carvedilol 2nicotinamide-beta-riboside 1empagliflozin 1Tablets 1Reverse Transcriptase Polymerase Chain Reaction 1Radiotherapy 1Paclitaxel 1Neoadjuvant Therapy 1Methotrexate 1Metformin 1Mass Spectrometry 1Lisinopril 1Leucovorin 1Lapatinib 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Gene Expression Profiling 1Fluorophotometry 1Filgrastim 1Fenofibrate 1Epirubicin 1Environmental Biomarkers 1Echocardiography 1Dexrazoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cardiotoxicity × Paclitaxel × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡